These three PD-L1 inhibitors were approved to treat different cancer patients: atezolizumab for NSCLC, avelumab for metastatic Merkel cell carcinoma, and durvalumab for locally advanced or metastatic urothelial carcinoma. The gene discussed is CD274; the disease is cancer.